Cystatin C tied to cumulative hearing impairment
Carla R. Schubert, from the University of Wisconsin in Madison, and colleagues obtained data from the Epidemiology of Hearing Loss Study to examine the correlation between cystatin C (as a biomarker and a marker of kidney function) and 20-year incidence of HI. Data were included for 863 participants aged 48 to 86 years with cystatin C data and no HI at baseline.
The researchers found that cystatin C was associated with increased risk of developing HI in models adjusted for age and sex (hazard ratio, 1.20; 95 percent confidence interval [CI], 1.07 to 1.34 per 0.2-mg/L increase in cystatin C concentration). After further adjustments, including those for education level and current smoking, the correlation was attenuated (hazard ratio, 1.11; 95 percent CI, 0.98 to 1.27 per 0.2-mg/L increase in cystatin C concentration). Cystatin C was used to determine low estimated glomerular filtration rate in both the age- and sex-adjusted model as well as in the multivariable-adjusted model and was significantly associated with the 20-year cumulative incidence of HI (hazard ratios, 1.70 [95 percent CI, 1.16 to 2.48] and 1.50 [95 percent CI, 1.02 to 2.22] for <60 to ≥60 mL/min/1.73 m², respectively).
"Reduced kidney function as estimated using cystatin C, but not cystatin C alone, was associated with the 20-year cumulative incidence of HI," the authors write.
Editorial (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.